Global NASH congress
Using the power of the world’s largest proteomic platform coupled with machine learning , clinical samples and known biopsy results were used to build proteomic models capable of staging steatosis, inflammation, ballooning and fibrosis, and diagnosing at-risk NASH. These models exhibit competitive performance vs. existing standard methods. Use-cases in drug development include a participant rule-out prior to biopsy and precision demonstration of pharmacodynamic mechanistic impacts on individual liver components with multiple longitudinal measurements. Combination of the liquid liver biopsy with other proteomic tests on the same platform can expand the assessment of drug impact to include changes in cardiovascular risk, insulin resistance, kidney function and body composition. This will result in smaller, faster and more comprehensive clinical trials in the future.
- Proteomic models capable of staging and diagnosing conditions for “at-risk” NASH
- Assessment of pharmacodynamic mechanisms over time
- Simultaneous drug impact assessment of multiple biological metrics
Stephen A. Williams, MD, PhD
Chief Medical Officer, SomaLogic
Steve Williams, MD, Ph.D, practiced medicine for over a decade at Charing Cross Hospital before joining Pfizer, where he became the VP and Worldwide Head of Clinical Technology. Since 2009 he has been the Chief Medical Officer at SomaLogic, where his focus has been on developing clinical tests using proteomic signatures.
WebinarUsing non-hypothesized based approaches for biomarker development
Current biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion (SRC).
WebinarAssessment of variability and normalization methods using the plasma 7K SomaScan® Assay v4.1
In this webinar, the speakers present the largest technical assessment of this platform to date based on a study of 2,050 samples across 22 plates.
WebinarThe proteomics of aging: how technology is advancing research
Please join us to hear four experts discuss the present challenges and opportunities for proteomics in aging research: Eric Morgen, COO of BioAge Labs; Paola Sebastiani, faculty biostatistician at Tufts Medical Center and PI on the Longevity Consortium; Birgit Schilling, associate professor, Buck Institute for Research on Aging; and Alessandro Ori, group leader at the Leibniz Institute on Aging.